drugset / Trial / NCT07697625

A Clinical Trial of MK-4082 in Healthy Participants (MK-4082-005)

NCT07697625

Phase 1 Not yet recruiting 18 enrolled Merck Sharp & Dohme LLC
NaSequentialOpen-labelBasic science

Summary

Researchers are looking for new weight loss medicines for people with higher body weight. The trial medicine, MK-4082, is different from similar weight loss medicines because people take it as a pill instead of an injection. Before giving a trial medicine to participants with a health condition, researchers first do trials in healthy participants to find a safe dose level (amount) of the trial medicine. The goal of this study is to learn what happens to MK-4082 in a person's body over time. Researchers will compare what happens to levels of MK-4082 in people's blood when it is taken without (Period 1) and with (Period 2) another medicine called diltiazem. Researchers also want to learn about the safety of MK-4082 taken with and without diltiazem and if people tolerate them.

Timeline

Start
2026-07-13
Primary completion
2026-09-28
Completion
2026-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Diltiazem Small molecule Oral
Subject MK-4082 Unknown Oral
Background Ondansetron Other / unclassified

Indications

No indication recorded.